MHRA-100345-PIP01-21

Key Facts

Active Substance
Active Substance:
  • Magrolimab
Invented Name
Not yet available
PIP Number MHRA-100345-PIP01-21
Pharmaceutical form(s)
  • Concentrate for solution for infusion
  • Age-appropriate dosage formulation for parenteral use
Therapeutic area
Therapeutic area:
  • Oncology
Conditions / Indications
  • Treatment of myelodysplastic syndromes (including juvenile myelomonocytic leukaemia)
  • Treatment of acute myeloid leukaemia
Route(s) of administration
Route(s) of administration:
  • Intravenous use
PIP applicant
Decision Type
Decision Type
P: decision agreeing on a paediatric investigation plan, with or without partial waiver(s) or deferrals(s)
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):Magrolimab.pdf
Published Date 25/05/2023